



## Prescription Pharmaceutical Products

PRODUCT	INDICATION <sup>1,2</sup>	TERRITORY						PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
<b>Oncology/Hematology</b>								
Tafasitamab	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Submitted	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Incyte
Pemigatinib	Metastatic cholangiocarcinoma		Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Marketed	Marketed	Marketed			Pre-registration	Helsinn
Aloxi®	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Approved <sup>3</sup>						Helsinn
Fostamatinib	Treatment of chronic immune thrombocytopenia		Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Rigel
Nerlynx®	Extended adjuvant breast cancer and metastatic breast cancer	Marketed						Puma
Trelstar®	Advanced prostate cancer	Marketed						Debiopharm
Vidaza®	Myelodysplastic syndrome		Marketed					Celgene (BMS)
Abraxane®	Metastatic pancreatic cancer		Marketed					Celgene (BMS)
Halaven®	Metastatic breast cancer and soft tissue sarcoma		Marketed	Marketed	Marketed		Marketed	Eisai
Lenvima®	Differentiated thyroid cancer and unresectable hepatocellular carcinoma		Marketed	Marketed	Marketed		Marketed	Eisai
Lenvima®	Advanced renal cell cancer		Marketed	Marketed			Marketed	Eisai
<b>BGx</b>								
Ladevina®	Multiple myeloma; myelodysplastic syndrome			Marketed	Marketed		Marketed	Own
Ladevina®	Mantle Cell Lymphoma; follicular lymphoma			Marketed			Marketed	Own
Zyvalix®	Metastatic prostate cancer			Marketed	Marketed		Marketed	Own
Karfib®	Relapsed or refractory multiple myeloma			Marketed			Approved	Own
Leprid®	Palliative treatment of advanced prostate cancer			Marketed				Own
Rembre®	Chronic myeloid leukemia			Marketed	Marketed		Marketed	Own
<b>Infectious Diseases</b>								
Ambisome®	Invasive fungal infection		Marketed					Gilead
Cresemba®	Invasive fungal infection		Marketed	Marketed	Marketed	Marketed	Marketed	Basilea
Impavido®	Leishmaniasis						Marketed	Own
<b>Other Specialty</b>								
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Marketed	Marketed	Marketed	Marketed	Marketed	Marketed	Own
Ibsrela®	IBS-C	Marketed						Ardelyx
Salofalk®	Ulcerative colitis			Marketed	Marketed		Marketed	Dr. Falk
Ursofalk®	Primary biliary cirrhosis			Marketed	Marketed		Marketed	Dr. Falk
Imvexxy™	Moderate-to-severe dyspareunia	Approved						TXMD
Bijuva™	Moderate-to-severe vasomotor symptoms due to menopause	Approved						TXMD
<b>BGx</b>								
Fibridoner®	Idiopathic pulmonary fibrosis			Marketed			Marketed	Own
Toliscrin® DPI	Pseudomonas aeruginosa lung infection in patients with cystic fibrosis			Marketed			Marketed	Own
Toliscrin® 1-2	Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli			Marketed			Marketed	Own
Tobradosa Haler®	Chronic lung infections due to Pseudomonas aeruginosa			Marketed			Marketed	Own

<sup>1</sup> Products in "pre-registration" have not yet been submitted for regulatory review and products in "submitted" are currently under regulatory review. The indication for all products classified as "pre-registration" or "submitted" is the anticipated indication upon regulatory approval.

<sup>2</sup> Refer to the "Products" section of Management's Discussion and Analysis for the three and nine-month periods ended September 30, 2022.

<sup>3</sup> Knight will begin commercial activities following a transition period from Helsinn current licensees.